Bafetinib

Research use only, not for human use.

A potent and selective dual Abl/Lyn tyrosine kinase inhibitor with IC50 of 5.9 nM and 198 nM, respectively.

A potent and selective dual Abl/Lyn tyrosine kinase inhibitor with IC50 of 5.9 nM and 198 nM, respectively; more potent and specific against Bcr-Abl than imatinib, also inhibits the phosphorylation of CrkL and ERK in BaF3/E255K cells; inhibits the phosphorylation of Bcr-Abl harboring the M244V, G250E, Q252H, Y253F, E255K, E255V, F317L, M351T, E355G, F359V, H396P, or F486S mutations, but does not inhibit the phosphorylation of the T315I mutant; prolonges the survival of mice injected with leukemic cells expressing all mutated Bcr-Abl.Blood Cancer Phase 2 Clinical.

Western Blot Analysis Cell Line:H292 Concentration:0.625, 1.25, 2.5 μM Incubation Time:24 h Result:Inhibited the expression of PD-L1 and c-Myc.

Animal Model:Murine inflammatory pain model Dosage:10 mg/kg Administration: i.g.Result: Inhibited PAR2-induced mechanical hyperalgesia.

INNO-406 | NS-187

Angiogenesis

Bcr-Abl

Abl|Lyn

Cancer

Blood cancer

859212-16-1

576.6154

C30H31F3N8O

>98% (HPLC)

DMSO: ≥ 42 mg/mL

O=C(NC1=CC=C(C)C(NC2=NC=CC(C3=CN=CN=C3)=N2)=C1)C4=CC=C(CN5C[C@@H](N(C)C)CC5)C(C(F)(F)F)=C4

Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-

(-20℃)

With Ice Pack

≥ 2 years